This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
By This Author:
Page 2 of 588

Celgene's Crohn's Disease Drug Candidate Highlighted in NEJM

By Adam Feuerstein

Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.

05:00PM 03/18/15

MannKind's Financial Health Complicated by Looming $100M Debt Payment

By Adam Feuerstein

MannKind is facing a cash shortfall unless it can settle with debt holders by August.

09:17AM 03/18/15

Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals

By Adam Feuerstein

When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.

10:26AM 03/17/15

As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High

By Adam Feuerstein

Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.

12:15PM 03/16/15

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing

By Adam Feuerstein

The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.

09:36AM 03/13/15

Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

09:00AM 03/13/15

Neuralstem Stock Plunges After Latest Study on ALS Drug

By Adam Feuerstein

Neuralstem is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease.

11:26AM 03/12/15

The Biotech Bubble Debate: Solid Science vs. Sky-High Valuations

By Adam Feuerstein

Biotech companies are experiencing an unprecedented run of scientific successes, but biotech stock valuations have never been more expensive.

09:25AM 03/12/15

Acadia Drug Is Delayed Again as CEO Announces Retirement

By Adam Feuerstein

Acadia admits that it can't seek approval for its Parkinson's psychosis drug this quarter, as promised. The company's CEO also resigned.

04:39PM 03/11/15

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?

By Adam Feuerstein

Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.

10:45AM 03/11/15

Page 2 of 588

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs